Lawrence Lee1,2,3, Nathalie Wong-Chong4,5, Justin J Kelly6, George J Nassif6, Matthew R Albert6, John R T Monson6. 1. Center for Colon and Rectal Surgery, Florida Hospital, Orlando, FL, USA. larry.lee@mcgill.ca. 2. Department of Surgery, McGill University Health Centre, Montreal, QC, Canada. larry.lee@mcgill.ca. 3. Colon and Rectal Surgery, McGill University Health Centre, 1001 Decarie Blvd, DS1-3310, Montreal, QC, H4A 3J1, Canada. larry.lee@mcgill.ca. 4. Department of Surgery, McGill University Health Centre, Montreal, QC, Canada. 5. Colon and Rectal Surgery, McGill University Health Centre, 1001 Decarie Blvd, DS1-3310, Montreal, QC, H4A 3J1, Canada. 6. Center for Colon and Rectal Surgery, Florida Hospital, Orlando, FL, USA.
Abstract
BACKGROUND: Minimally invasive surgery (MIS) may improve surgical recovery and reduce time to adjuvant systemic therapy after colon cancer resection. The objective of this study was to determine the effect of MIS on the initiation of adjuvant systemic therapy and survival in patients with stage III colon cancer. METHODS: The 2010-2014 National Cancer Database was queried for patients with resected stage III colon adenocarcinoma, and divided into MIS, which included laparoscopic and robotic approaches, and open surgery. Propensity-score matching was used to balanced open and MIS groups. The main outcome measures were delayed initiation of adjuvant systemic therapy (defined as > 8 weeks after surgery) and 5-year overall survival (OS). Multiple Cox regression was performed to identify independent predictors for 5-year OS, including an interaction between delayed systemic therapy and MIS, and adjusted for clustering at the hospital level. RESULTS: There were 86,680 patients that were included in this study. Overall, 45% (38,713) underwent MIS colectomy, of which 93% underwent laparoscopic and 7% robotic surgery. After matching, 33,183 open patients were balanced to 33,183 MIS patients. Patient, tumor, and facility characteristics were similar in the matched cohort. More patients in the MIS group received adjuvant therapy within 8 weeks of surgery (49% vs. 42%, p < 0.001), and fewer MIS patients did not receive any systemic therapy (30% vs. 35%, p < 0.001). Delayed initiation of systemic therapy > 8 weeks was associated with worse 5-year OS (HR 1.27, 95%CI 1.19-1.36). MIS was independently associated with improved survival (HR 0.92, 95%CI 0.86-0.97). This relationship remained even if 90-day mortality was excluded. CONCLUSIONS: MIS approaches are associated with less delay to the initiation of adjuvant systemic therapy and improved survival in patients with stage III colon adenocarcinoma. Surgeons should favor MIS approaches for the treatment of stage III colon adenocarcinoma whenever possible.
BACKGROUND: Minimally invasive surgery (MIS) may improve surgical recovery and reduce time to adjuvant systemic therapy after colon cancer resection. The objective of this study was to determine the effect of MIS on the initiation of adjuvant systemic therapy and survival in patients with stage III colon cancer. METHODS: The 2010-2014 National Cancer Database was queried for patients with resected stage III colon adenocarcinoma, and divided into MIS, which included laparoscopic and robotic approaches, and open surgery. Propensity-score matching was used to balanced open and MIS groups. The main outcome measures were delayed initiation of adjuvant systemic therapy (defined as > 8 weeks after surgery) and 5-year overall survival (OS). Multiple Cox regression was performed to identify independent predictors for 5-year OS, including an interaction between delayed systemic therapy and MIS, and adjusted for clustering at the hospital level. RESULTS: There were 86,680 patients that were included in this study. Overall, 45% (38,713) underwent MIS colectomy, of which 93% underwent laparoscopic and 7% robotic surgery. After matching, 33,183 open patients were balanced to 33,183 MIS patients. Patient, tumor, and facility characteristics were similar in the matched cohort. More patients in the MIS group received adjuvant therapy within 8 weeks of surgery (49% vs. 42%, p < 0.001), and fewer MIS patients did not receive any systemic therapy (30% vs. 35%, p < 0.001). Delayed initiation of systemic therapy > 8 weeks was associated with worse 5-year OS (HR 1.27, 95%CI 1.19-1.36). MIS was independently associated with improved survival (HR 0.92, 95%CI 0.86-0.97). This relationship remained even if 90-day mortality was excluded. CONCLUSIONS: MIS approaches are associated with less delay to the initiation of adjuvant systemic therapy and improved survival in patients with stage III colon adenocarcinoma. Surgeons should favor MIS approaches for the treatment of stage III colon adenocarcinoma whenever possible.
Authors: Adan Z Becerra; Christian P Probst; Mohamedtaki A Tejani; Christopher T Aquina; Maynor G González; Bradley J Hensley; Katia Noyes; John R T Monson; Fergal J Fleming Journal: Surgery Date: 2015-05-29 Impact factor: 3.982
Authors: Genevieve M Boland; George J Chang; Alex B Haynes; Yi-Ju Chiang; Ryaz Chagpar; Yan Xing; Chung-Yuan Hu; Barry W Feig; Y Nancy You; Janice N Cormier Journal: Cancer Date: 2012-12-21 Impact factor: 6.860
Authors: A C R K Bos; F N van Erning; Y R B M van Gestel; G J M Creemers; C J A Punt; M G H van Oijen; V E P P Lemmens Journal: Eur J Cancer Date: 2015-09-07 Impact factor: 9.162
Authors: Linda X Jin; Dominic E Sanford; Malcolm Hart Squires; Lindsey E Moses; Yan Yan; George A Poultsides; Konstantinos I Votanopoulos; Sharon M Weber; Mark Bloomston; Timothy M Pawlik; William G Hawkins; David C Linehan; Carl Schmidt; David J Worhunsky; Alexandra W Acher; Kenneth Cardona; Clifford S Cho; David A Kooby; Edward A Levine; Emily Winslow; Neil Saunders; Gaya Spolverato; Graham A Colditz; Shishir K Maithel; Ryan C Fields Journal: Ann Surg Oncol Date: 2016-03-22 Impact factor: 5.344
Authors: Marco Milone; Michele Manigrasso; Nunzio Velotti; Stefania Torino; Antonietta Vozza; Giovanni Sarnelli; Giovanni Aprea; Francesco Maione; Nicola Gennarelli; Mario Musella; Giovanni Domenico De Palma Journal: Int J Colorectal Dis Date: 2019-05-06 Impact factor: 2.571
Authors: Karin Atgm Wasmann; Charlotte El Klaver; Jarmila Dw van der Bilt; Susan van Dieren; Iris D Nagtegaal; Cornelis Ja Punt; Bert van Ramshorst; Albert M Wolthuis; Johannes Hw de Wilt; André D'Hoore; Hjalmar C van Santvoort; Pieter J Tanis Journal: Cancer Manag Res Date: 2019-07-29 Impact factor: 3.989